Inhibrx Biosciences has released its financial results for Q1 2026, detailing significant developments in their drug pipeline and fiscal performance.

What Inhibrx Biosciences, Inc. changed in their own words, quarter over quarter.

Inhibrx Biosciences will host a live webcast to discuss primary results from the Phase 2 study of INBRX-106 for HNSCC, focusing on efficacy and safety.

Inhibrx Biosciences, Inc. has reported its financial results for the second quarter of 2026, detailing important developments in their clinical trials and financial outlook.

Inhibrx Biosciences (Nasdaq: INBX) reported second quarter 2026 results, highlighting clinical progress and a major debt financing. The company entered a Second Amendment to its Loan and Security Agreement with Oxford Finance, providing up to $325.0 million in additional gross proceeds, including $100.0 million funded in July 2026.The FDA accepted Inhibrx’s BLA for ozekibart (INBRX-109) in conventional chondrosarcoma with a PDUFA goal date of April 14, 2027. New Phase 1 colorectal cancer cohorts were initiated, with interim data expected in Q1 2027. Q2 2026 R&D expense was $23.9 million and G&A was $8.3 million, driving a net loss of $36.7 million or $2.34 per share. Cash and cash equivalents were $133.3 million at June 30, 2026 and $219.5 million as of August 6, 2026, while long‑term debt rose to $176.3 million, and stockholders’ equity turned to a deficit of $53.0 million.

Inhibrx issued warrants for 21,457 shares at $93.21; the capital will support ozekibart and INBRX-106 ahead of key data readouts.

Clinical trial results show Inhibrx’s Ozekibart significantly improves survival measures in advanced chondrosarcoma, where no approved options exist, and demonstrates encouraging high response rates i...

Positive topline results from the registrational ChonDRAgon study investigating ozekibart (INBRX-109) as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma were recently reported. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not all […]

Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced updated interim data from its Phase 1/2 study evaluating ozekibart (INBRX-109) in combination with FOLFIRI in patients with locally advanced or metastatic, unresectable colorectal cancer (CRC).

Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced positive topline results from the registrational ChonDRAgon study (n= 206) investigating ozekibart (INBRX-109) as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma.

If Inhibrx Biosciences' ozekibart gets the FDA go-ahead, it would become the first targeted therapy approved for chondrosarcoma.

Inhibrx said ozekibart reduced the risk of disease progression or death by 52% in patients with a common form of bone cancer. The biotech plans to file for approval by the end of June 2026.

Click to view the official SEC document.

Reported Monday, Jun 15 - 9:16am EDT (TheFly subscription required to read more.)

Reported Tuesday, Apr 21 - 4:09pm EDT (TheFly subscription required to read more.)

Reported Thursday, Oct 23 - 4:19pm EDT (TheFly subscription required to read more.)

Inhibrx Biosciences has achieved significant progress with its therapy Ozekibart, now under FDA review for treating aggressive chondrosarcoma.